Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2295 - Active chronic hepatitis B increases the risk of liver metastasis of colorectal cancer- a retrospective clinical study of 7187 consecutive cases of newly diagnosed colorectal cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Lei Zhao


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


L. Zhao1, L. Song2, J. Cao3, Y. Yang4

Author affiliations

  • 1 Hepatobiliopancreatic Surgery, Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 2 Medical Oncology, 1st Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 3 Hbp Surgery, The Affiliated Hospital of Qingdao University, 266000 - Qingdao/CN
  • 4 Hbp Surgery, Shandong Cancer Hospital and I, 250117 - Jian/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2295


The effect of concomitant chronic hepatitis B (CHB) infection on the risk of colorectal liver metastasis (CRLM) has not been definitively elucidated. Many clinicians believe that CHB is “protective” and although previous reports support their presumption, these studies were limited by small sample size, mixed types of chronic hepatitis and heterogeneous therapies.


To explore this issue, we retrospectively studied 7187 newly diagnosed colorectal cancer (CRC) patients. The definitions and diagnostic procedures of synchronous CRLM (synCRLM) were as per our previous report.


The prevalence of HBsAg+ was 5.12% (364/7111) and HBeAg+ was 1.25% (76/6075). The overall prevalence of synCRLM was 8.72% (627/7187) and was significantly higher in HBsAg+ patients than HBsAg- patients (13.40% vs. 8.54%, P = 0.031). SynCRLM was also more prevalent in HBeAg+ patients compared to HBeAg- patients (19.70% vs. 10.17%, P = 0.031). In univariate logistic regression analysis, HBeAg+ had the highest hazard ratio (HR) [2.947, P < 0.001] and was more than twice that of HBsAg + (HR: 1.435, P = 0.032). In the subsequent multivariate analysis with other significant factors, HBeAg+ was still the strongest predictor of synCRLM (HR: 2.322, P = 0.044), the HR of HBsAg+ was 1.686 (P = 0.024).


This study focuses only on the newly diagnosed synCRLM and eliminates the effect of various adjuvant and neoadjuvant therapy. In our previous study of 4033 CRC patients and contrary to much of the reported literature, HBsAg+ was associated with significantly increased prevalence of CRLM. HBeAg+ also trended toward increased CRLM prevalence but didn’t reach statistical significance. When expanded to 7187 subjects, HBeAg+ is finally proved to be a predictor of CRLM, with a HR much higher than that of HBsAg+. Unlike the minimal chance of HBsAg loss, HBeAg seroconversion and HBV-DNA repression can be achieved in many CHB patients with current anti-viral therapies. In summary, HBeAg+ is a clinical risk factor for CRLM that can be readily identified and addressed. Whether antiviral treatment can decrease the risk of CRLM is definitely worth further study.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


National Natural Science Fund of China (No.81872400).


L. Zhao: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: MSD. J. Cao: Speaker Bureau / Expert testimony: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.